Edwards Lifesciences
1,296 hedge funds and large institutions have $45.6B invested in Edwards Lifesciences in 2024 Q2 according to their latest regulatory filings, with 121 funds opening new positions, 464 increasing their positions, 466 reducing their positions, and 90 closing their positions.
34% more first-time investments, than exits
New positions opened: 121 | Existing positions closed: 90
7% more funds holding in top 10
Funds holding in top 10: 14 → 15 (+1)
1% more funds holding
Funds holding: 1,281 → 1,296 (+15)
0.44% more ownership
Funds ownership: 81.48% → 81.93% (+0.44%)
0% less repeat investments, than reductions
Existing positions increased: 464 | Existing positions reduced: 466
2% less capital invested
Capital invested by funds: $46.7B → $45.6B (-$1.17B)
7% less call options, than puts
Call options by funds: $276M | Put options by funds: $297M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$348M |
| 2 |
SFFS
Stonehage Fleming Financial Services
St. Helier,
Jersey
|
+$204M |
| 3 |
UBS AM
Chicago,
Illinois
|
+$137M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$122M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$86.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$224M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$179M |
| 3 |
BlackRock
New York
|
-$128M |
| 4 |
JP Morgan Chase
New York
|
-$81.7M |
| 5 |
State Street
Boston,
Massachusetts
|
-$67.9M |
EW Hedge Fund Activity: Q2 2024 in Review
1,296 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q2 2024, worth a combined $45.6B — down 2.5% from $46.7B a quarter earlier.
Buyers outnumbered sellers: 121 funds opened new EW positions and 90 closed out — a net gain of 31 holders — while 464 added to existing stakes and 466 trimmed.
The largest buyer was AllianceBernstein, adding an estimated $348M. The largest seller was Point72 Asset Management, cutting an estimated $224M.
- 1,296 institutional investors held Edwards Lifesciences (EW) as of Q2 2024, up from 1,281 in Q1 2024.
- Funds reported $45.6B of Edwards Lifesciences stock for Q2 2024, down 2.5% quarter-over-quarter.
- 121 funds opened new Edwards Lifesciences positions in Q2 2024 and 90 closed out, a net change of +31 holders.
- The largest Edwards Lifesciences buyer in Q2 2024 was AllianceBernstein, an estimated $348M added.
- The largest Edwards Lifesciences seller in Q2 2024 was Point72 Asset Management, an estimated $224M sold.
Based on aggregated 13F filings for Q2 2024.